DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • United States
  • /
  • Healthcare
Author Program NEWCreate Narrative
BAX logo

Baxter International Inc. Stock Price

NYSE:BAX Community·US$12.6b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 42 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

BAX Share Price Performance

US$24.18
-0.31 (-1.27%)
​
US$28.73
Fair Value
US$24.18
-0.31 (-1.27%)
15.8% undervalued intrinsic discount
US$28.73
Fair Value
Price US$24.18
AnalystConsensusTarget US$28.73
AnalystLowTarget US$23.00
AnalystHighTarget US$34.14
Sat, 15 Aug 26
Fair ValueUS$28.73
Share Pricen/a

BAX Community Narratives

AN
AnalystConsensusTarget
AnalystConsensusTarget's
Fair Value
·
Fair Value US$28.73 15.8% undervalued intrinsic discount

BAX: Near-Term Headwinds Will Resolve As Margins Stabilize Into 2026

0users have liked this narrative
0users have commented on this narrative
18users have followed this narrative
AN
AnalystLowTarget
AnalystLowTarget's
Fair Value
·
Fair Value US$23 5.1% overvalued intrinsic discount

Global Healthcare Spending And Aging Will Squeeze Hospital Revenues

1users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
AnalystHighTarget
AnalystHighTarget's
Fair Value
·
Fair Value US$34.14 29.2% undervalued intrinsic discount

Aging Populations And Rising Chronic Disease Will Expand Care Access

0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
BAX logo
Baxter International
5.1% overvalued intrinsic discount

Global Healthcare Spending And Aging Will Squeeze Hospital Revenues

View narrative
AN
AnalystLowTarget
AnalystLowTarget
Updated 3 Sep
Read Narrative
BAX logo
Baxter International
15.8% undervalued intrinsic discount

BAX: Near-Term Headwinds Will Resolve As Margins Stabilize Into 2026

View narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget
Updated 15 Aug
Read Narrative
BAX logo
Baxter International
29.2% undervalued intrinsic discount

Aging Populations And Rising Chronic Disease Will Expand Care Access

View narrative
AN
AnalystHighTarget
AnalystHighTarget
Updated 16 Jul
Read Narrative

Trending Discussion

No trending discussion available.

Recently Updated Narratives

AN
AnalystLowTarget
BAX logo

BAX: Margin And Earnings Uncertainty Will Drive A Cautious Outlook

Fair Value: US$23 5.1% overvalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystConsensusTarget
BAX logo

BAX: Q2 Execution And Cash Tender Offers Will Shape Margin Narrative

Fair Value: US$28.73 15.8% undervalued intrinsic discount
18 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystHighTarget
BAX logo

BAX: Segment Realignment And Margin Execution Will Drive Future Repricing Potential

Fair Value: US$34.14 29.2% undervalued intrinsic discount
2 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative

Snowflake Analysis

Undervalued with moderate growth potential.

1 Risk
3 Rewards
View Full Analysis

Baxter International Inc. Key Details

US$11.5b

Revenue

US$7.6b

Cost of Revenue

US$3.9b

Gross Profit

US$4.9b

Other Expenses

-US$968.0m

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
-1.87
34.10%
-8.44%
153.1%
View Full Analysis

About BAX

Founded
1931
Employees
37500
CEO
Andrew Hider
WebsiteView website
www.baxter.com

Baxter International Inc., through its subsidiaries, provides a portfolio of healthcare products in the United States. The company operates through three segments: Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals. It offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; inhaled anesthetics; generic injectable pharmaceuticals; surgical hemostat and sealant products; advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space comprising operating room integration technologies, precision positioning devices, and other accessories. The company also provides specialty injectable pharmaceuticals, inhaled anesthetics, and drug compounding services. Its products are used in hospitals, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors’ offices, kidney dialysis centers, and patients at home under physician supervision. The company sells its products through direct sales force, independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers. It operates in Eastern Europe, the Middle East, Africa, Latin America, Asia, Western Europe, Canada, Japan, Australia, and New Zealand. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.

Recent BAX News & Updates

User avatar
Narrative Update • Sep 03

BAX: Margin And Earnings Uncertainty Will Drive A Cautious Outlook

The analyst fair value estimate for Baxter International has been revised from $17.00 to $23.00 as analysts respond to a series of higher Street price targets that reflect recent earnings, updated segment reporting, and improved sales momentum, while still flagging questions around longer term growth and margins. Analyst Commentary Recent Street research on Baxter International points to a more balanced stance.

Recent updates

No updates

Baxter International Inc. Competitors

HCA logo

HCA Healthcare

Symbol: NYSE:HCA
Market cap: US$91.3b
ELV logo

Elevance Health

Symbol: NYSE:ELV
Market cap: US$86.1b
CI logo

Cigna Group

Symbol: NYSE:CI
Market cap: US$73.5b
BSX logo

Boston Scientific

Symbol: NYSE:BSX
Market cap: US$65.2b
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide